Austin Research Group Research Reports

Title	Published	Price
Therapeutic Area Clinical Intelligence: Type-2 Diabetes Pipeline By: Austin Research Group Diabetes affects more than an estimated 18 million people in the United States and approximately 194 million adults worldwide. The World Health Organization projects that the number of people with diabetes will double to 366 \| more... Search inside this report	6/1/2008	$4,500.00
Therapeutic Clinical Intelligence - Rheumatoid Arthritis By: Austin Research Group The world-wide market for Rheumatoid Arthritis (RA) therapeutics has undergone significant change over the past 5-10 years with the introduction of biologics. These biologic products, specifically, the anti-TNF-alpha monoclonal antibodies—Enbrel, Humira, and Remicade—are dominating the \| more... Search inside this report	12/1/2007	$5,000.00
Trial TRAX Multiple Sclerosis Clinical Trial Monitoring Brief By: Austin Research Group The Multiple Sclerosis (MS) therapeutic market will experience a significant shift in power in the next five years. The current market leaders, Interferons and Copaxone, could lose their dominance to novel orally formulated and biologic \| more... Search inside this report	10/1/2007	$1,000.00
Alzheimer's Disease Clinical Trial Monitoring Brief By: Austin Research Group Austin Research Group’s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on \| more...	10/1/2007	$700.00
Rheumatoid Arthritis Clinical Trial Monitoring Brief By: Austin Research Group Austin Research Group’s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on \| more...	8/1/2007	$600.00
Therapeutic Clinical Intelligence - Psoriasis By: Austin Research Group The world-wide market for Psoriasis therapeutics is estimated to be valued at $1-$3 billion annually. There are currently only 3 biologic competitors vying for share of this market. The Anti-TNF-a monoclonal antibodies—Enbrel, Humira, and Remicade—currently \| more... Search inside this report	7/1/2007	$900.00
Therapeutic Clinical Intelligence-Multiple Sclerosis By: Austin Research Group Competitive intelligence on the clinical trials of products on the market and in development for Multiple Sclerosis Scope of Report The scope of this report will primarily concentrate on the R&D competitive landscape for \| more...	4/9/2007	$4,100.00
Therapeutic Clinical Intelligence-Inflammatory Bowel Disease By: Austin Research Group Crohn¡¦s Disease Market In 2007, Remicade (infliximab/Anti-TNF-fÑ), the current market leader in the treatment of moderate-to-severe Crohn¡¦s Disease (CD), is expected to experience fierce challenges for patient share from 2-3 new Anti-TNF class competitors; Humira, \| more... Search inside this report	3/8/2007	$3,100.00
Title	Published	Price

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2008, All Rights Reserved, MarketResearch.com
7/23/2008 - 2